Keywords:
гепатоцеллюлярная карцинома, рак печени, эпидемиология, скрининг, выживаемость, заболеваемость, смертность, ВОЗ, IARC, GCOReferences
Choo SP, Tan WL, Goh BKP, Tai WM, Zhu AX. Comparison of hepatocellular carcinoma in Eastern versus Western populations. Cancer 2016; 122: 3430–3446.
Altekruse SF, McGlynn KA, Reichman ME. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol 2009; 27:1485–1491.
Singal AG, Pillai A, Tiro J. Early detection, curative treatment, and survival rates for hepatocellular carcinoma surveillance in patients with cirrhosis: a meta-analysis. PLoS Med 2014;11:e1001624
International Agency for Research on Cancer/World Health Organization. Global Cancer Observatory. Cancer Today: Data visualization tools for exploring the global cancer burden in 2020. http:// gco.iarc.fr/today. Accessed 16 Dec 2021.
Heimbach JK, Kulik LM, Finn RS, Sirlin CB, Abecassis MM, Roberts LR, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology 2018; 67:358–380.
Yu JS, Kim KW, Kim EK, Lee JT, Yoo HS. Contrast enhancement of small hepatocellular carcinoma: usefulness of three successive early image acquisitions during multiphase dynamic MR imaging. AJR Am J Roentgenol 1999;173:597–604.
Torzilli G, Minagawa M, Takayama T, Inoue K, Hui AM, Kubota K, et al. Accurate preoperative evaluation of liver mass lesions without fine-needle biopsy. Hepatology 1999; 30:889–893.
European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol. 2018;69 (1):182–236. Erratum in: J Hepatol. 2019;70(4):817
Singal AG, Llovet JM, Yarchoan M et al (2023) AASLD practice guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma. Hepatology. https:// doi. org/ 10. 1097/ HEP. 00000 00000 000466
Marrero JA, Kulik LM, Sirlin CB, et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the Study of Liver Diseases. Hepatology. 2018;68(2):723–50.
Korean Liver Cancer Association (KLCA) and National Cancer Center (NCC) Korea (2022) 2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma. Clin Mol Hepatol 28:583–705. https:// doi. org/ 10. 3350/ cm h.2022. 0294
Omata M, Cheng AL, Kokudo N et al (2017) Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int 11:317–370. https:// doi. org/ 10. 1007/ s12072- 017- 9799-9
Wang CH, Wey KC, Mo LR, et al. Current trends and recent advances in diagnosis, therapy, and prevention of hepatocellular carcinoma. Asian Pac J Cancer Prev. 2015;16(9):3595–3604. doi:10.73 14/apjcp.2015.16.9.3595
Tanaka H. Current role of ultrasound in the diagnosis of hepatocellular carcinoma. J Med Ultrason. 2020;47(2):239–255. doi:10.1007/s10396-020-01012-y
Jia PF, Gao WP. Malignant liver cancer ultrasonic image processing and analysis based on MATLAB. Tissue Engineering Research and Clinical Rehabilitation. 2009;13(43):8523–8526. doi: 10.39 69/j.issn.1673-8225.2009.43.026
Ren FY, Piao XX, Jin AL. Efficacy of ultrasonography and alpha-fetoprotein on early detection of hepatocellular carcinoma. World J Gastroenterol. 2006;12(29): 46564659. doi:10.3748/wjg. v12.i29.4 656
Demirtas CO, Gunduz F, Tuney D, et al. Annual contrast-enhanced magnetic resonance imaging is highly effective in the surveillance of hepatocellular carcinoma among cirrhotic patients. Eur J Gastroenterol Hepatol. 2020;32(4):517–523. doi:10.1097/ MEG.0000000000001528
Terminology and Diagnostic Criteria Committee, Japan Society of Ultrasonics in Medicine. Ultrasound diagnostic criteria for hepatic tumors. J Med Ultrason. 2014; 41:113–23.
Maringhini A, Cottone M, Sciarrino E, et al. Ultrasonography and alpha-fetoprotein in diagnosis of hepatocellular carcinoma in cirrhosis. Dig Dis Sci. 1988; 33:47–51.
Maturen KE, Wasnik AP, Bailey JE, et al. Posterior acoustic enhancement in hepatocellular carcinoma. J Ultrasound Med. 2011; 30:495–9.
Itai Y, Ohtomo K, Ohnishi S, et al. Ultrasonography of small hepatic tumors. Radiat Med. 1987; 5:14–9.
Choi BI, Kim CW, Han MC, et al. Sonographic characteristics of small hepatocellular carcinoma. Gastrointest Radiol. 1989; 14:255–61.
Kutami R, Nakashima Y, Nakashima O, et al. Pathomorphologic study on the mechanism of fatty change in small hepatocellular carcinoma of humans. J Hepatol. 2000; 33:282–9.
Kutami R, Nakashima Y, Nakashima O, et al. Pathomorphologic study on the mechanism of fatty change in small hepatocellular carcinoma of humans. J Hepatol. 2000; 33:282–9.
Higashi T, Tobe K, Asano K, et al. Ultrasonographic characteristics of small hepatocellular carcinoma. Acta Med Okayama. 1988; 42:151–7.
Yoshida T, Matsue H, Okazaki N, et al. Ultrasonographic differentiation of hepatocellular carcinoma from metastatic liver cancer. J Clin Ultrasound. 1987; 15:431–7.
Inoue T, Kudo M, Watai R, et al. Differential diagnosis of nodular lesions in cirrhotic liver by post-vascular phase contrast-enhanced US with Levovist: comparison with superparamagnetic iron oxide magnetic resonance images. J Gastroenterol. 2005; 40:1139–47.
Minami Y, Kudo M. Hepatic malignancies: correlation between sonographic findings and pat-hological features. World J Radiol. 2010; 2:249–56.
Inoue T, Hyodo T, Korenaga K, et al. Kupffer phase image of Sonazoid-enhanced US is useful in predicting a hypervascularization of non-hypervascular hypointense hepatic lesions detected on Gd-EOB-DTPA-enhanced MRI: a multicenter retrospective study. J Gastroenterol. 2016; 52:144–52.
Tanaka S, Kitamura T, Imaoka S, et al. Hep-atocellular carcinoma: sonographic and histologic correlation. AJR Am J Roentgenol. 1983;140: 701–7.
Wernecke K, Henke L, Vassallo P, et al. Pathologic explanation for hypoechoic halo seen on sonograms of malignant liver tumors: an in vitro correlative study. AJR Am J Roentgenol. 1992; 159:10 11–6.
Wernecke K, Vassallo P, Bick U, et al. The distinction between benign and malignant liver tumors on sonography: value of a hypoechoic halo. AJR Am J Roentgenol. 1992; 159:1005–9.
Makuuchi M, Hasegawa H, Yamazaki S, et al. Ultrasonic characteristics of the small hepatocellular carcinoma. Ultrasound Med Biol. 1983; Suppl 2:489–91.
Tochio H, Tomita S, Kudo M, et al. The efferent blood flow of early hepatocellular carcinoma and borderline lesions: demonstration by color Doppler imaging. J Med Ultrason. 2002; 29:205–9.
Tochio H, Kudo M. Afferent and efferent vessels of premalignant and overt hepatocellular carcinoma: observation by color Doppler imaging. Intervirology. 2004; 47:144–53.
Yen H-H. Progress in the ultrasonographic microvascular imaging. J Med Ultrasound. 2018;26: 1–2.
Kudo M, Tochio H. Intranodular blood supply correlates well with biological malignancy grade determined by tumor growth rate in pathologically proven hepatocellular carcinoma. Oncology. 2008; 75:55–64.
Marelli C. Preliminary experience with NC100100, a new ultrasound contrast agent for intravenous injection. Eur Radiol. 1999;9: S343–S346346.
Albrecht T, Hoffmann CW, Schmitz SA, et al. Phase-inversion sonography during the liver-specific late phase of contrast enhancement: improved detection of liver metastases. AJR Am J Roentgenol. 2001; 176:1191–8.
Blomley MJK, Sidhu PS, Cosgrove DO, et al. Do different types of liver lesions differ in their uptake of the microbubble contrast agent SH U 508A in the late liver phase? Early Exp Radiol. 2001; 220:6 61–7.
Blomley MJK, Albrecht T, Cosgrove DO, et al. Improved imaging of liver metastases with stimulated acoustic emission in the late phase of enhancement with the US contrast agent SH U 508A: early experience. Radiology. 1999; 210:409–16.
Numata K, Luo W, Morimoto M, et al. Contrast enhanced ultrasound of hepatocellular carcinoma. World J Radiol. 2010; 2:68–82.
Quaia E, Calliada F, Bertolotto M, et al. Characterization of focal liver lesions with contrast-specific US modes and a sulfur hexafluoride-filled microbubble contrast agent: diagnostic performance and confidence. Radiology. 2004; 232:420–30.
Leen E, Ceccotti P, Kalogeropoulou C, et al. Prospective multicenter trial evaluating a novel method of characterizing focal liver lesions using contrast-enhanced sonography. Am J Roentgenol. 2006; 186:1551–9.
Nicolau C, Vilana R, Catalá V, et al. Importance of evaluating all vascular phases on contrast-enhanced sonography in the differentiation of benign from malignant focal liver lesions. Am J Roentgenol. 2006; 186:158–67.
Leen E, Ceccotti P, Moug SJ, et al. Potential value of contrast-enhanced intraoperative ultrasonography during partial hepatectomy for metastases: an essential investigation before resection? Ann Surg. 2006; 243:236–40.
Yang H, Liu G-J, Lu M-D, et al. Evaluation of the vascular architecture of hepatocellular carcinoma by micro flow imaging: pathologic correlation. J Ultrasound Med. 2007; 26:461–7.
Trillaud H, Bruel JM, Valette PJ, et al. Characterization of focal liver lesions with SonoVue-enhanced sonography: international multicenter-study in comparison to CT and MRI. World J Gastroenterol. 2009; 15:3748–56.
Liu GJ, Xu HX, Xie XY, et al. Does the echogenicity of focal liver lesions on baseline gray-scale ultrasound interfere with the diagnostic performance of contrast-enhanced ultrasound? Eur Radiol. 2009; 19:1214–22.
Yanagisawa K, Moriyasu F, Miyahara T, et al. Phagocytosis of ultrasound contrast agent microbubbles by Kupffer cells. Ultrasound Med Biol. 2007; 33:318–25.
Lim AKP, Patel N, Eckersley RJ, et al. Evidence for spleen-specific uptake of a microbubble contrast agent: a quantitative study in healthy volunteers. Radiology. 2004; 231:785–8.
Moriyasu F, Itoh K. Efficacy of perflubutane microbubble-enhanced ultrasound in the characterization and detection of focal liver lesions: phase 3 multicenter clinical trial. Am J Roentgenol. 2009;193: 86–95.
Shunichi S, Hiroko I, Fuminori M, et al. Definition of contrast enhancement phases of the liver using a perfluoro-based microbubble agent, perflubutane microbubbles. Ultrasound Med Biol. 2009;35: 1819–27.
Tang A., Cruite I., Mitchell D.G., Sirlin C.B. Hepatocellular carcinoma imaging systems: Why they exist, how they have evolved, and how they differ. Abdom. Radiol. 2018; 43:3–12. doi: 10.1007/s00 261-017-1292-3.
Kulkarni N.M., Fung A., Kambadakone A.R., Yeh B.M. Computed Tomography Techniques, Protocols, Advancements, and Future Directions in Liver Diseases. Magn. Reson. Imaging Clin. N. Am. 2021; 29:305–320. doi: 10.1016/j.mric.2021.05.002.